Effect of pharmacogenomic testing on pediatric mental health outcome: a 6-month follow-up

Area of Science:

• Pharmacogenomics
• Child and Adolescent Psychiatry
• Clinical Pharmacology

Background:

• Pharmacogenomic testing (PGT) aims to optimize medication selection and dosing based on genetic profiles.
• Pediatric mental health conditions like anxiety, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD) often require complex medication management.
• The utility of PGT in guiding pediatric psychiatric treatment remains an area of active investigation.

Purpose of the Study:

• To evaluate the impact of pharmacogenomic testing (PGT) on the clinical management of pediatric patients diagnosed with anxiety, MDD, and ADHD.
• To compare treatment outcomes and medication adjustment frequency between pediatric patients who received PGT and those who did not.

Main Methods:

• Retrospective case-control study design.
• Analysis of psychiatric diagnoses, medication histories, and genetic profiles including CYP450, SLC6A4, HTR2A, COMT, and MTHFR.
• Comparison of clinical improvement and medication changes between PGT and non-PGT groups.

Main Results:

• No significant difference in overall clinical improvement between the PGT and control groups.
• A significantly higher number of medication changes occurred in the PGT group.
• Improved treatment response observed in ADHD patients receiving PGT, correlated with COMT gene status; no difference in MDD or anxiety response.

Conclusions:

• Pharmacogenomic testing demonstrated potential utility in managing pediatric ADHD, but its benefit for pediatric anxiety and MDD appears limited.
• Clinical decisions regarding PGT in pediatric mental health should consider cost-effectiveness, clinical utility, and healthcare provider experience.
• Study limitations include small sample size and potential selection bias, necessitating further research.